Alpha Cognition Inc. to Present New Clinical Data on ZUNVEYL® (Benzgalantamine) and Cholinesterase Inhibitors at Upcoming Scientific Meetings

Reuters

2025/10/15

<a href="https://laohu8.com/S/ACOGD">Alpha Cognition Inc.</a> to Present New Clinical Data on ZUNVEYL® (Benzgalantamine) and Cholinesterase Inhibitors at Upcoming Scientific Meetings

Alpha Cognition Inc., a commercial-stage biopharmaceutical company focused on neurodegenerative diseases, has announced plans to present new clinical data on cholinesterase inhibitors and its product ZUNVEYL® (benzgalantamine) at two upcoming scientific meetings. The company will share insights at the American Society of Consultant Pharmacists (ASCP) Annual Meeting scheduled for October 23-25, 2025, and the Neuroscience Education Institute (NEI) Annual Congress scheduled for November 6-9, 2025. The presentations will include poster sessions on topics such as acetylcholinesterase inhibitors and psychotropic medication use, persistence of therapy in Alzheimer's disease and related dementias, methodologies for switching between acetylcholinesterase inhibitors, and the effects of these treatments on sleep and mortality in Alzheimer's disease. The results are set to be presented at these future meetings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Cognition Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251014774412) on October 14, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2575422452"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575422452\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575422452?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-15 04:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575422452","market":"nz","top_or_hot":-1,"title":"Alpha Cognition Inc. to Present New Clinical Data on ZUNVEYL® (Benzgalantamine) and Cholinesterase Inhibitors at Upcoming Scientific Meetings","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ACOGD\">Alpha Cognition Inc.</a> to Present New Clinical Data on ZUNVEYL® (Benzgalantamine) and Cholinesterase Inhibitors at Upcoming Scientific Meetings\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ACOGF\">Alpha Cognition Inc.</a>, a commercial-stage biopharmaceutical company focused on neurodegenerative diseases, has announced plans to present new clinical data on cholinesterase inhibitors and its product ZUNVEYL® (benzgalantamine) at two upcoming scientific meetings. The company will share insights at the American Society of Consultant Pharmacists (ASCP) Annual Meeting scheduled for October 23-25, 2025, and the Neuroscience Education Institute (NEI) Annual Congress scheduled for November 6-9, 2025. The presentations will include poster sessions on topics such as acetylcholinesterase inhibitors and psychotropic medication use, persistence of therapy in Alzheimer's disease and related dementias, methodologies for switching between acetylcholinesterase inhibitors, and the effects of these treatments on sleep and mortality in Alzheimer's disease. The results are set to be presented at these future meetings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ACOG\">Alpha Cognition</a> Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251014774412) on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alpha Cognition Inc. to Present New Clinical Data on ZUNVEYL® (Benzgalantamine) and Cholinesterase Inhibitors at Upcoming Scientific Meetings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlpha Cognition Inc. to Present New Clinical Data on ZUNVEYL® (Benzgalantamine) and Cholinesterase Inhibitors at Upcoming Scientific Meetings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-15 04:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ACOGD\">Alpha Cognition Inc.</a> to Present New Clinical Data on ZUNVEYL® (Benzgalantamine) and Cholinesterase Inhibitors at Upcoming Scientific Meetings\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ACOGF\">Alpha Cognition Inc.</a>, a commercial-stage biopharmaceutical company focused on neurodegenerative diseases, has announced plans to present new clinical data on cholinesterase inhibitors and its product ZUNVEYL® (benzgalantamine) at two upcoming scientific meetings. The company will share insights at the American Society of Consultant Pharmacists (ASCP) Annual Meeting scheduled for October 23-25, 2025, and the Neuroscience Education Institute (NEI) Annual Congress scheduled for November 6-9, 2025. The presentations will include poster sessions on topics such as acetylcholinesterase inhibitors and psychotropic medication use, persistence of therapy in Alzheimer's disease and related dementias, methodologies for switching between acetylcholinesterase inhibitors, and the effects of these treatments on sleep and mortality in Alzheimer's disease. The results are set to be presented at these future meetings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ACOG\">Alpha Cognition</a> Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251014774412) on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL36Z4zc:1","article_id":"2575422452","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575422452","pubTimestamp":1760473822,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alpha Cognition Inc. to Present New Clinical Data on ZUNVEYL  and Cholinesterase Inhibitors at Upcoming Scientific Meetings. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Cognition Inc. published the original content used to generate this news brief via Business Wire  on October 14, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ACOG":"ALPHA COGNITION INC"},"translate_title":"Alpha Cognition Inc.将展示ZUNVEYL的新临床数据®（苯并加兰他敏）和胆碱酯酶抑制剂在即将举行的科学会议上","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACOG":0.9},"content_text":"Alpha Cognition Inc. to Present New Clinical Data on ZUNVEYL® (Benzgalantamine) and Cholinesterase Inhibitors at Upcoming Scientific Meetings\n    \n\nAlpha Cognition Inc., a commercial-stage biopharmaceutical company focused on neurodegenerative diseases, has announced plans to present new clinical data on cholinesterase inhibitors and its product ZUNVEYL® (benzgalantamine) at two upcoming scientific meetings. The company will share insights at the American Society of Consultant Pharmacists (ASCP) Annual Meeting scheduled for October 23-25, 2025, and the Neuroscience Education Institute (NEI) Annual Congress scheduled for November 6-9, 2025. The presentations will include poster sessions on topics such as acetylcholinesterase inhibitors and psychotropic medication use, persistence of therapy in Alzheimer's disease and related dementias, methodologies for switching between acetylcholinesterase inhibitors, and the effects of these treatments on sleep and mortality in Alzheimer's disease. The results are set to be presented at these future meetings.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Cognition Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251014774412) on October 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}